Optimization of time interval for the measurement of plasma lipids for cardiovascular disease risk assessment

被引:0
作者
Sampson, Maureen [1 ]
Wolska, Anna [2 ]
Zubiran, Rafael [2 ]
Cole, Justine [1 ,2 ]
Amar, Marcelo [2 ]
Remaley, Alan T. [2 ]
机构
[1] NIH, Dept Lab Med, Clin Ctr, Bethesda, MD USA
[2] NHLBI, Lipoprotein Metab Lab, Translat Vasc Med Branch, NIH, 10 Ctr Dr,Bldg 10 Rm, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Cardiovascular disease; cholesterol; lipids; lipid testing; risk score; testing frequency; TASK-FORCE; AGE; ASSOCIATION; CHOLESTEROL; PREVENTION; GUIDELINES; SOCIETY;
D O I
10.1080/14737159.2024.2306127
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background Lipid testing for atherosclerotic cardiovascular disease (ASCVD) risk is often performed every 4-6 years, but we hypothesized that the optimum time interval may vary depending on baseline risk.Research Design and Methods Using lipid values and other risk factors from the National Health and Nutrition Examination Survey (NHANES) (n = 9,704), we calculated a 10-year risk score with the pooled-cohort equations. Future risk scores were predicted by increasing age and projecting systolic blood pressure (SBP) and lipid changes, using the mean-percentile age group change in NHANES for SBP (n = 17,329) and the Lifelines Cohort study for lipids (n = 133,540). The crossing of high and intermediate-risk thresholds were calculated by time to determine optimum intervals for lipid testing.Results Time to crossing risk thresholds depends on baseline risk, but the mean increase in the risk score plateaus at 1% per year for those with a baseline 10-year risk greater than 15%. Based on these findings, we recommend the following maximum time intervals for lipid testing: baseline risk < 15%: 5-years, 16%: 4-years, 17%: 3-years, 18%: 2-years, and 19%: <= 1-year.Conclusions Testing patients for lipids who have a higher baseline risk more often could identify high-risk patients sooner, allowing for earlier and more effective therapeutic intervention.
引用
收藏
页码:123 / 133
页数:11
相关论文
共 50 条
  • [21] Medical imaging in the assessment of cardiovascular disease risk
    Alcantara, Juan Manuel A.
    Idoate, Fernando
    Labayen, Idoia
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2023, 26 (05) : 440 - 446
  • [22] The Need for Individualized Risk Assessment in Cardiovascular Disease
    Lim, Hui Yin
    Burrell, Louise M.
    Brook, Rowena
    Nandurkar, Harshal H.
    Donnan, Geoffrey
    Ho, Prahlad
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (07):
  • [23] New views on the relationship of plasma lipids to cardiovascular disease
    Tracy, RP
    Tracy, PB
    CIRCULATION, 1997, 95 (06) : 1347 - 1348
  • [24] Implementing absolute cardiovascular disease risk assessment into pathology collection services
    Pagano, Lisa
    Sharman, James E.
    Nash, Rose
    Sutton, Laura
    Donovan, Shaun
    Owens, Daniel
    Murfett, Leigh
    Heathcote, Sheridan
    Wells, Gudrun
    Zurynski, Yvonne
    Sarkies, Mitchell
    Chapman, Niamh
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2024, : 1239 - 1250
  • [25] Atherogenic index of plasma and risk of cardiovascular disease among Cameroonian postmenopausal women
    Nansseu, Jobert Richie N.
    Moor, Vicky Jocelyne Ama
    Nouaga, Murielle Elsa D.
    Zing-Awona, Bertrand
    Tchanana, Gladys
    Ketcha, Arthur
    LIPIDS IN HEALTH AND DISEASE, 2016, 15
  • [26] Utility of Cardiovascular Imaging to Refine Cardiovascular Disease (CVD) Risk Assessment
    Marcio Sommer Bittencourt
    Edward A. Hulten
    Khurram Nasir
    Ron Blankstein
    Current Cardiovascular Risk Reports, 2014, 8 (4) : 1 - 10
  • [27] Diet Quality Assessment and the Relationship between Diet Quality and Cardiovascular Disease Risk
    Petersen, Kristina S.
    Kris-Etherton, Penny M.
    NUTRIENTS, 2021, 13 (12)
  • [28] Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis
    Marina Loaeza-del Castillo, Aurora
    Gaytan-Santillan, Alhely
    Lopez-Tello, Alma
    Valdes-Almanza Merit, Merit
    del Pilar Milke-Garcia, Maria
    Flores-Rodriguez, Jorge
    Alvirde-Garcia, Ulices
    ANNALS OF HEPATOLOGY, 2019, 18 (06) : 879 - 882
  • [29] Plasma lipoprotein (a) and tissue plasminogen activator are associated with increased risk of atherosclerotic cardiovascular disease
    Mayyas, Fadia
    Omar, Eman Bani
    HELIYON, 2022, 8 (07)
  • [30] Construction of a risk assessment model of cardiovascular disease in a rural Chinese hypertensive population based on lasso-Cox analysis
    Ouyang, Nanxiang
    Li, Guangxiao
    Wang, Chang
    Sun, Yingxian
    JOURNAL OF CLINICAL HYPERTENSION, 2022, 24 (01) : 38 - 46